MOLN
Molecular Partners AG
NASDAQ · Healthcare · Biotechnology · CH
$4.11
−5.52%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.18x
- Price / sales
- —
- Price / cash flow
- -2.47x
Enterprise value
- Enterprise value
- $77.4M
- EV / sales
- —
- EV / EBITDA
- -1.13x
- EV / EBIT
- -1.08x
- Market cap
- $157.4M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026